Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2017 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. The company is Insmed, developing ALIS for NTM lung disease. They are pre-commercial, planning a launch. They have hired a sales force, are building patient support infrastructure, etc. They talk about their own precommercial activities. They mention discussions with payers, but that's about pricing and access. They talk about the FDA, regulatory, NDA filing. They talk about their own clinical trials. They talk about Japan as a market. But do they narrate what counterparties (like customers, partners, distributors, payers) are themselves doing and scaling? The company is not yet selling. They are preparing for launch. They have no customers yet. They have a partner for manufacturing (Patheon) but they mention building out an additional third-party manufacturing site with Patheon, but that's about their own supply. They don't describe Patheon's own expansion as driving Insmed's growth. They talk about physicians and patients, but those are not counterparties they supply. They talk about payers, but only in terms of access requirements, not about payers' own programs scaling. The essence of the question: management speaks about counterparties' business as though it were part of its own, describing their ramps, launches, etc., and the company is already inside that growth. Here, the company is pre-revenue, not yet approved. They are not supplying anyone yet. They are planning to launch. So they are not already inside any counterparty's growth. They are hoping to win approval and then sell. So the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.